Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P51398
UPID:
RT29_HUMAN
Alternative names:
28S ribosomal protein S29, mitochondrial; Death-associated protein 3; Ionizing radiation resistance conferring protein
Alternative UPACC:
P51398; B4DP59; B4DY62; E7EM60; Q13044; Q68CT7; Q96Q20
Background:
The Small ribosomal subunit protein mS29, also known as 28S ribosomal protein S29, mitochondrial, Death-associated protein 3, and Ionizing radiation resistance conferring protein, plays a crucial role in mediating interferon-gamma-induced cell death. This protein is a component of the mitochondrial ribosome, essential for protein synthesis and cellular energy production.
Therapeutic significance:
Understanding the role of Small ribosomal subunit protein mS29 could open doors to potential therapeutic strategies. Its involvement in cell death pathways suggests a possible target for diseases where cell death is dysregulated.